U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H14O6S2
Molecular Weight 246.3042
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUSULFAN

SMILES

CS(=O)(=O)OCCCCOS(=O)(=O)C

InChI

InChIKey=COVZYZSDYWQREU-UHFFFAOYSA-N
InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C6H14O6S2
Molecular Weight 246.3042
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB01008 https://en.wikipedia.org/wiki/Busulfan

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic). Most common adverse reactions (incidence greater than 60%) were: myelosuppression, nausea, stomatitis, vomiting, anorexia, diarrhea, insomnia, fever, hypomagnesemia, abdominal pain, anxiety, headache, hyperglycemia and hypokalemia. Itraconazole and acetaminophen can decrease busulfan clearance. Phenytoin increases hepatic clearance of busulfan.

CNS Activity

CNS Penetrant
2344
Curator's Comment:: Busulfan is a small, highly lipophilic molecule that easily crosses the blood brain barrier.

Originator

Chester Beatty Research Institute
1
Sources: Lichtman M., 'Hematology: Landmark Papers of the Twentieth Century' (2000), P. 598. ISBN-13 | 978-0124485105

Approval Year

1954
118
Targets

Targets

Primary TargetPharmacologyConditionPotency
Crosslinking Agent
76
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8043
MYLERAN

Approved Use

BUSULFEX is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. BUSULFEX is an alkylating drug indicated for: •Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML) (1)

Launch Date

-4.89715204E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1222 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
0.8 mg/kg 4 times / day steady-state, intravenous
dose: 0.8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
BUSULFAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1167 μM × min
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
0.8 mg/kg 4 times / day steady-state, intravenous
dose: 0.8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
BUSULFAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.35 h
OTHER GOV
https://www.ema.europa.eu/en/documents/product-information/busilvex-epar-product-information_en.pdf
0.8 mg/kg 4 times / day steady-state, intravenous
dose: 0.8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
BUSULFAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
67.6%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
0.8 mg/kg 4 times / day steady-state, intravenous
dose: 0.8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
BUSULFAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
40 mg/m2 4 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 4 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 4 times / day
Co-administed with::
etoposide. i.v.(60 mg/kg; over 4 h on day4)
cyclophosphamide. i.v.(120 mg/kg over 1h on days 3, and 2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
Page: p.407
unhealthy, 1.2–17.2
n = 6
Health Status: unhealthy
Condition: Acute Myelogenous Leukemia|Myelodysplastic syndrome
Age Group: 1.2–17.2
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
Page: p.407
Disc. AE: Hepatotoxicity...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
Page: p.407
4 mg/kg 4 times / day multiple, oral
Overdose
Dose: 4 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Page: p.127
unhealthy, 14
n = 1
Health Status: unhealthy
Condition: Myelodysplastic syndrome
Age Group: 14
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Page: p.127
Disc. AE: Seizures...
AEs leading to
discontinuation/dose reduction:
Seizures
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Page: p.127
18 mg/kg single, oral
Overdose
Dose: 18 mg/kg
Route: oral
Route: single
Dose: 18 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Page: p.126
unhealthy, 48
n = 1
Health Status: unhealthy
Condition: Myelodysplastic syndrome
Age Group: 48
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Page: p.126
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Page: p.126
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic myelogenous leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Page: p.1
Disc. AE: Myelosuppression, Seizures...
AEs leading to
discontinuation/dose reduction:
Myelosuppression (severe)
Seizures
Venoocclusive disease
Fetal damage
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Page: p.1
AEs

AEs

AESignificanceDosePopulation
Hepatotoxicity Disc. AE
40 mg/m2 4 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 4 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 4 times / day
Co-administed with::
etoposide. i.v.(60 mg/kg; over 4 h on day4)
cyclophosphamide. i.v.(120 mg/kg over 1h on days 3, and 2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
Page: p.407
unhealthy, 1.2–17.2
n = 6
Health Status: unhealthy
Condition: Acute Myelogenous Leukemia|Myelodysplastic syndrome
Age Group: 1.2–17.2
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
Page: p.407
Seizures Disc. AE
4 mg/kg 4 times / day multiple, oral
Overdose
Dose: 4 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Page: p.127
unhealthy, 14
n = 1
Health Status: unhealthy
Condition: Myelodysplastic syndrome
Age Group: 14
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Page: p.127
Fetal damage Disc. AE
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic myelogenous leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Page: p.1
Seizures Disc. AE
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic myelogenous leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Page: p.1
Venoocclusive disease Disc. AE
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic myelogenous leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Page: p.1
Myelosuppression severe
Disc. AE
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic myelogenous leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1601

inhibitor
1467
inhibitor
1604
inhibitor
1702
inhibitor
1475

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1383

CYP2A6
627

CYP2C19
1325

CYP2E1
790

BSEP
376

OATP1B1
733

OATP1B3
657

MRP2
346

MRP3
150

MRP4
194
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1532
 no [IC50 >10 uM]
CYP2A6
659
 no [IC50 >10 uM]
CYP2C19
1392
 no [IC50 >10 uM]
CYP2C9
1648
 no [IC50 >10 uM]
CYP2D6
1738
 no [IC50 >10 uM]
CYP2E1
871
 no [IC50 >10 uM]
BSEP
377
 no [IC50 >1000 uM]
MRP2
434
 no [IC50 >133 uM]
MRP3
200
 no [IC50 >133 uM]
MRP4
226
 no [IC50 >133 uM]
CYP3A4
1772
 no [IC50 >812 uM]
OATP1B1
748
 yes
OATP1B3
666
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1601
 likely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1507
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:28901
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28901
ChemicalBook
CB2105891
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2105891
ChemicalBook
CB72673681
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB72673681
MolPort
MolPort-001-783-406
https://www.molport.com/shop/molecule-link/MolPort-001-783-406
Selleck Chemicals
Busulfan(Busulfex)
http://www.selleckchem.com/products/Busulfan(Busulfex).html
ZINC
ZINC000001530572
http://zinc15.docking.org/substances/ZINC000001530572
eMolecules
486878
https://www.emolecules.com/cgi-bin/more?vid=486878
PubMed

PubMed

TitleDatePubMed
Endocardial fibrosis following busulfan treatment.
1975 Feb 3
Up-regulation of glutathione S-transferase activity in enterocytes of young children.
1999 Dec
Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
2000 Aug
A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation.
2000 Nov
Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
2000 Sep
Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma.
2001
Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation.
2001 Apr
Bone marrow transplantation for T-B- severe combined immunodeficiency disease in Athabascan-speaking native Americans.
2001 Apr
Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution.
2001 Apr
[Complications after high dose therapy and autologous stem cell transplantation. Retrospective study of an unselected patient sample].
2001 Apr 15
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
2001 Aug
Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry.
2001 Aug
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
2001 Aug
Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis.
2001 Aug 1
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
2001 Aug 1
Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
2001 Feb
The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia.
2001 Feb
Idiopathic pneumonia syndrome following myeloablative chemotherapy and autologous transplantation.
2001 Feb
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
2001 Feb 1
Mouse carotid artery ligation induces platelet-leukocyte-dependent luminal fibrin, required for neointima development.
2001 Feb 2
Systemic fusariosis after a preparative regimen including thiotepa, VP-16 and busulfan used for blood stem cell transplantation in Hodgkin's disease.
2001 Jan
The biology and treatment of chronic myelogenous leukemia.
2001 Jan
Autologous peripheral blood stem cell transplantation for patients with malignancies: the Tri-Service General Hospital experience.
2001 Jul
Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant.
2001 Jul
High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
2001 Jul
Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning.
2001 Jul
Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression.
2001 Jul 15
Arsenic trioxide in the management of acute promyelocytic leukaemia.
2001 Jul-Aug
A cautionary tale: how to delete mouse haemopoietic stem cells with busulphan.
2001 Jun
Congenital sideroblastic anaemia successfully treated using allogeneic stem cell transplantation.
2001 Jun
Estrogen receptor-alpha is required by the supporting somatic cells for spermatogenesis.
2001 Jun 10
Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial.
2001 Jun 15
Pharmacodynamics of high-dose chemotherapy.
2001 Mar
A single institutional experience with 43 pregnancies in essential thrombocythemia.
2001 Mar
Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma.
2001 Mar
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
2001 Mar
Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.
2001 Mar
Synthesis and in vitro cytotoxicity of novel long chain busulphan analogues.
2001 Mar 26
Hepatic venoocclusive disease: a major complication of hematopoietic stem cell transplantation in cancer patients.
2001 Mar-Apr
Hydroxyurea and periodicity in myeloproliferative disease.
2001 May
Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria.
2001 May
O6-Benzylguanine potentiates BCNU but not busulfan toxicity in hematopoietic stem cells.
2001 May
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
2001 Oct
Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.
2001 Oct
Monitoring of busulfan area under the curve: estimation by a single measurement.
2001 Oct
[Hematopoietic stem cell transplantation with busulfanthiotepa-cyclophosphamide conditioning for pediatric patients with high-risk acute lymphoblastic leukemia].
2001 Sep
Allogeneic bone marrow transplantation-mediated transfer of specific immunity against Toxocara canis associated with excessive IgE.
2001 Sep
Neonatal bone marrow transplantation for severe combined immunodeficiency.
2001 Sep
Sexual differentiation of germ cell deficient gonads in the medaka, Oryzias latipes.
2001 Sep 1
New method for thyroid transplantation across major histocompatibility complex barriers using allogeneic bone marrow transplantation.
2001 Sep 27
Patents

Patents

05994391
1
06107494
1
20010004454
38
JP2006502184A
39
JP2007525670A
139
JP2008533019A
33
JP2011525178A
21
JP2011528275A
417
JP2012500104A
106
JP4663232B2
15

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Oral administration: adult dose range for remission induction is 4 to 8 mg, total dose, daily. Dosing on a weight basis is the same for both pediatric patients and adults, approximately 60 mcg/kg of body weight or 1.8 mg/m2 of body surface, daily. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf456fc7-3a79-47f7-8acc-600b5e2f0dc2
0.8 mg per kg intravenously six hours for four consecutive days for a total of 16 doses
Route of Administration: Intravenous
In Vitro Use Guide
P39 myeloid cells were incubated with busulfan in concentrations ranging from 10 to 100 microg/ml for 2, 4 or 8 h, then washed and cultured in busulfan-free medium for 72 h.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:53:06 UTC 2021
Edited
by admin
on Fri Jun 25 20:53:06 UTC 2021
Record UNII
G1LN9045DK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUSULFAN
EMA EPAR   EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
BUSULFANUM [WHO-IP LATIN]
Common Name English
BUSULFAN [MI]
Common Name English
BUSULFAN [JAN]
Common Name English
BUSULFAN [EMA EPAR]
Common Name English
BUSILVEX
Brand Name English
BUSULFAN [EP]
Common Name English
BUSULFAN [USP MONOGRAPH]
Common Name English
BUSULFAN [MART.]
Common Name English
BUSULFAN [IARC]
Common Name English
BUSULFAN [VANDF]
Common Name English
1,4-BUTANEDIOL DIMETHANESULPHONATE
Systematic Name English
TETRAMETHYLENE DI(METHANESULFONATE)
Systematic Name English
BUSULFAN [HSDB]
Common Name English
LEUCOSULFAN
Common Name English
SULPHABUTIN
Common Name English
1,4-BUTANEDIYL DIMETHANESULFONATE
Systematic Name English
1,4-BUTANEDIOL, DIMETHANESULFONATE
Systematic Name English
BUSULFAN [WHO-DD]
Common Name English
1,4-BUTANEDIOL DIMETHANESULFONATE
Systematic Name English
BUSULPHAN
Systematic Name English
BUSULFEX
Brand Name English
BUSULFAN FRESENIUS KABI
Brand Name English
NSC-750
Code English
NCI-C01592
Code English
BUSULFAN [ORANGE BOOK]
Common Name English
BUSULFAN [INN]
Common Name English
MYELOSANUM [WHO-IP]
Common Name English
1,4-BUTANEDIOL, DIMETHANESULPHONATE
Systematic Name English
BUSULFAN [EP MONOGRAPH]
Common Name English
BUSULFAN [WHO-IP]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS BUSULFAN FRESENIUS KABI (AUTHORIZED: HEMATOPOIETIC STEM CELL TRANSPLANTATION)
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
FDA ORPHAN DRUG 140700
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
FDA ORPHAN DRUG 394513
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
NDF-RT N0000000236
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
FDA ORPHAN DRUG 160402
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
FDA ORPHAN DRUG 81694
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
LIVERTOX 130
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
FDA ORPHAN DRUG 161602
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
NDF-RT N0000175558
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
EU-Orphan Drug EU/3/00/011
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
WHO-VATC QL01AB01
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
FDA ORPHAN DRUG 105897
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
EMA ASSESSMENT REPORTS BUSILVEX (AUTHORIZED: HEMATOPOIETIC STEM CELL TRANSPLANTATION)
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
FDA ORPHAN DRUG 83094
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
WHO-ATC L01AB01
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
IARC Busulfan
NCI_THESAURUS C222
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
Code System Code Type Description
MESH
D002066
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
EVMPD
SUB05993MIG
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
WIKIPEDIA
BUSULFAN
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
RXCUI
1828
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB01008
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
BUSULFAN
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY Description: A white, crystalline powder. Solubility: Very slightly soluble in water; sparingly soluble in acetone R; slightly soluble in ethanol (~750 g/l) TS. Category: Cytotoxic drug. Storage: Busulfan should be kept in a well-closed container, protected from light. Additional information: CAUTION: Busulfan must be handled with care, avoiding contact with the skin and inhalation of airborne particles. Definition: Busulfan contains not less than 98.5% and not more than 100.5% of C6H14O6S2, calculated with reference to the dried substance.
CAS
55-98-1
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
IUPHAR
7136
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
DRUG CENTRAL
438
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
PUBCHEM
2478
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
NCI_THESAURUS
C321
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
HSDB
7605
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
FDA UNII
G1LN9045DK
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
LACTMED
Busulfan
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
MERCK INDEX
M2778
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
200-250-2
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
INN
564
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
EPA CompTox
55-98-1
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
ChEMBL
CHEMBL820
Created by admin on Fri Jun 25 20:53:06 UTC 2021 , Edited by admin on Fri Jun 25 20:53:06 UTC 2021
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of BUSULFAN
ACTIVE MOIETY
http://apps.who.int/phint/pdf/b/Jb.6.1.63.pdf
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966